REG - Scancell Hlds - Scancell presenting at 21st CIMT Annual Meeting

Scancell HoldingsAnnouncement

09/05/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240509:nRSI6993Na&default-theme=true

RNS Number : 6993N  Scancell Holdings Plc  09 May 2024

9 May 2024

 

Scancell Holdings plc

("Scancell" or the "Company")

 

 

Scancell announces multiple upcoming presentations at the 21(st) CIMT Annual
Meeting

 

 

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for
the treatment of cancer, today announces that multiple abstracts have been
accepted for an oral and as poster presentations at the 21st Association for
Cancer Immunotherapy CIMT Annual Meeting being, taking place in Mainz,
Germany, on 15-17 May 2024.

 

Impressive clinical data of SCIB1, supported by functional T cell responses to
the TRP2 and gp100 peptides which can be detected in patients post
vaccination, will be presented by Head of Translational Research, Dr Samantha
Paston. The posters will show the isolation of specific TCRs that recognise
post translationally modified peptides and the application of
Anti-Sialyl-di-Lewis-a as a CAR-T.  Professor Lindy Durrant, Chief Executive
Officer of Scancell.  "We are thrilled to have a robust presence at this
year's CIMT meeting. These presentations are a reflection of Scancell's high
quality science and expertise in developing innovative immunotherapies to
address unmet needs in cancer."

 

CIMT is Europe's largest meeting focused on cancer immunotherapy research and
development. Every year, the CIMT Annual Meeting connects the global cancer
immunotherapy community in the heart of Europe. As the largest meeting focused
on cancer immunotherapy research and development in Europe, CIMT invites
international participants for high-level scientific exchange, collaboration,
and education focused on cancer immunotherapy.

 

Oral Presentation details are as follows:

 

Title:                       A DNA plasmid melanoma
cancer vaccine, SCIB1, combined with nivolumab + ipilimumab in patients with
advanced unresectable melanoma

Session:                 Short talk session VI

Date and Time:    Thursday, 17(th) May 2024 between 10.30am-12.00pm

Location:               Rheingoldhalle Congress Center Mainz

Abstract No:         139

Speaker:                Dr Samantha Paston

Authors:                Samantha Paston, Heather Shaw, Poulam
Patel, Miranda Payne, Satish Kumar, Sarah Danson, Martin Highley, Clare
Barlow, Robert Miller, Gaëlle Cane, Joseph Chadwick, Sabaria Shah, Victoria
Brentville, Rachael Metheringham, Georgia Goodhew, Fayaz Master, Lindy
Durrant.

 

Poster Presentation details are as follows:

 

Title:                       Isolation and
characterisation of TCRs that recognise Citrullinated and Homocitrullinated
post translationally modified peptides

Session                   Poster session I

Date and Time      Wednesday, 15(th) May 2024 between 3.00pm-5.30pm

Location                 Rheingoldhalle Congress Center Mainz

Abstract No:         34

Authors:                Samantha Paston, Ruhul Choudhury,
Sabaria Shah, Gaëlle Cane, Joseph Chadwick, Rachael Metheringham, Fayaz
Master, Rebecca Herbertson, Lindy Durrant.

 

 

Title:                      Anti-Sialyl-di-Lewisa CAR T
cells for effective tumor therapy of gastrointestinal tumor

Session                   Poster session I

Date and Time     Wednesday, 15(th) May 2024 between 3.00pm-5.30pm

Location                 Rheingoldhalle Congress Center Mainz

Abstract No:         5

Authors:                I. Charles, K. Cook, G. Cane, B. Kaira,
A. Skinner, A. Wright, M. Vankemmelbeke, R. Metheringham, V. Brentville, L.
Durrant

 

 

The posters will be made available on the Company's website following the
conference at  https://www.scancell.co.uk/antibody-publications
(https://www.scancell.co.uk/antibody-publications)

 

 

 For further information, please contact:

 Scancell Holdings plc                                                +44 (0) 20 3709 5700
 Dr Jean-Michel Cosséry, Non-Executive Chairman
 Professor Lindy Durrant, CEO

 Stifel Nicolaus Europe Limited (Nominated Adviser and Joint Broker)  +44 (0) 20 7710 7600
 Nicholas Moore/Samira Essebiyea
 Nick Harland (Corporate Broking)

 WG Partners LLP (Joint Broker)                                       +44 (0) 20 3705 9330

 David Wilson/Claes Spang/Sathesh Nadarajah/Erland Sternby

 Panmure Gordon (UK) Limited (Joint Broker)                           +44 (0) 20 7886 2500
 Freddy Crossley/Emma Earl (Corporate Finance)
 Rupert Dearden (Corporate Broking)

 ICR Consilium                                                        +44 (0) 20 3709 5700
 Mary-Jane Elliott/Angela Gray/Lindsey Neville                        scancell@consilium-comms.com (mailto:scancell@consilium-comms.com)

About Scancell

 

Scancell is a clinical stage biopharmaceutical company that is leveraging its
proprietary research, built up over many years of studying the human adaptive
immune system, to generate novel medicines to treat significant unmet needs in
cancer. The Company is building a pipeline of innovative products by utilising
its four technology platforms: Moditope® and ImmunoBody® for vaccines and
GlyMab® and AvidiMab® for antibodies.

 

Adaptive immune responses include antibodies and T cells (CD4 and CD8), both
of which can recognise damaged or infected cells. In order to destroy such
cancerous or infected cells, Scancell uses either vaccines to induce immune
responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs.
The Company's unique approach is that its innovative products target
modifications of proteins and lipids. For the vaccines (Moditope® and
ImmunoBody® ) this includes citrullination and homocitrullination of
proteins, whereas its mAb portfolio targets glycans or sugars that are added
onto proteins and / or lipids (GlyMab® ) or enhances the potency of
antibodies and their ability to directly kill tumour cells (AvidiMab® ).

 

For further information about Scancell, please visit:
https://www.scancell.co.uk/ (https://www.scancell.co.uk/)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCAPMLTMTBMBJI